Does Stage III multiple myeloma mean my cancer is terminal or untreatable?

No. Unlike solid tumors where Stage IV means distant organ metastasis, multiple myeloma staging only goes up to Stage III (or Stage IV in the R2-ISS point calculator) and measures baseline tumor load, kidney filtering of sβ2M, and cell division speed. With modern anti-CD38 quadruplet regimens and stem cell transplantation, many Stage III patients achieve Complete Response (CR), Minimal Residual Disease (MRD) negativity, and multi-year survival.

What is the difference between ISS, R-ISS, and R2-ISS staging?

ISS (2005) uses only two blood tests—serum beta-2 microglobulin (sβ2M) and albumin—to estimate tumor bulk. R-ISS (2015) is the current universal standard that adds serum LDH and three high-risk FISH chromosome abnormalities: del(17p), t(4;14), and t(14;16). R2-ISS (2022, endorsed in NCCN v2.2027) uses an additive 0 to 5.0 point score (adding chromosome 1q21 gain/amplification) to divide the broad R-ISS Stage II group into four sharper risk tiers.

Why did my elevated kidney creatinine automatically put me into ISS Stage III?

Beta-2 microglobulin (sβ2M) is a small protein shed by myeloma cells that is normally filtered out by the kidneys. When myeloma free light chains temporarily slow down kidney function, sβ2M builds up in the bloodstream to ≥ 5.5 mg/L, automatically triggering ISS Stage III even if your genetic risk is standard. If your bone marrow FISH genetics and blood LDH are normal, your R-ISS stage steps down to Stage II.

If my FISH report shows a 1q21 gain (+1q) or t(4;14), am I automatically high-risk?

Not necessarily. Under the latest IMS/IMWG Consensus Genomic Staging and Mayo Clinic mSMART 4.0 criteria, an isolated 1q21 gain adds only +0.5 points in R2-ISS (low-intermediate risk), and an isolated t(4;14) without chromosome 1 abnormalities often responds nearly as well as standard-risk disease. True high-risk biology is defined by del(17p) in ≥ 20% of plasma cells, a TP53 mutation, or 'Double-Hit' combinations where t(4;14)/t(14;16) co-occurs with +1q or del(1p32).

Will my myeloma stage drop back to Stage I once my M-protein reaches zero?

No. Your ISS, R-ISS, or R2-ISS stage is a one-time baseline snapshot recorded at initial diagnosis and remains fixed forever. Once treatment begins, your hematologist measures success using IMWG response criteria—Partial Response (PR, ≥ 50% drop), Very Good Partial Response (VGPR, ≥ 90% drop), Complete Response (CR), and MRD negativity (fewer than 1 myeloma cell per 100,000 to 1,000,000 bone marrow cells).

What is the most important mistake to avoid during my baseline bone marrow biopsy?

Never allow a lab to run bone marrow FISH genetic testing without CD138 magnetic plasma cell enrichment, and never start high-dose steroids before your biopsy and FDG-PET/CT scan are finished (unless facing a medical emergency). Without CD138 purification, diluted marrow samples yield false-normal genetic results, and early steroid pulses can obscure baseline PET-CT bone lesions and MRD clonotype identification.

Back to Guidelines

newly-diagnosed

Multiple Myeloma Staging: Why Stage III Is Not Terminal

Name: Multiple Myeloma Staging: Why Stage III Is Not Terminal | CMDN
Creator: CMDN Editorial Team

How to read your staging report and the essential tests you need before starting treatment

Medical Disclaimer: This guide is synthesized from international clinical consensus guidelines and peer-reviewed literature. It is for educational purposes only and does not substitute for professional medical advice. Always consult your oncology team regarding diagnostic and treatment decisions.

💡 The Short Answer

In multiple myeloma, Stage III does not mean terminal or metastatic solid cancer; instead, international staging systems—ISS, R-ISS, and the additive R2-ISS point score (0 to 5.0 points)—measure baseline tumor burden and genetic risk. By combining serum beta-2 microglobulin (sβ2M ≥ 5.5 mg/L), serum albumin (< 3.5 g/dL or < 35 g/L), LDH, and CD138-enriched iFISH cytogenetics such as del(17p) (≥ 20%), t(4;14), and 1q21+, your hematologist-oncologist can tailor risk-adapted quadruplet therapy to achieve deep Minimal Residual Disease (MRD) negativity (10⁻⁵ to 10⁻⁶).

Why This Matters

Seeing the words "Stage III Multiple Myeloma" on a diagnostic report often triggers immediate fear. Because most patients and caregivers are familiar with solid tumors like lung, breast, or colon cancer, three widespread misconceptions frequently cause unnecessary distress at diagnosis:

Equating Stage III myeloma with terminal Stage IV solid cancer: Patients often assume Stage III means the cancer has metastasized beyond control, not realizing that myeloma only has three classic stages (I, II, and III) that measure blood biomarkers and genetics rather than physical organ spread.
Confusing baseline staging with ongoing treatment response: Many families expect their stage number to drop to "Stage I" after chemotherapy clears the bone marrow, unaware that baseline staging stays fixed while remission is tracked through Complete Response (CR) and MRD negativity.
Rushing into treatment before completing the 4-pillar baseline workup: Starting steroids or chemotherapy before obtaining a CD138-enriched bone marrow FISH panel, a 24-hour urine collection, and a whole-body FDG-PET/CT or low-dose CT permanently erases vital baseline genetic and imaging clues.

This guide explains how doctors calculate your ISS, R-ISS, and R2-ISS stage in plain terms, why Stage III patients routinely achieve deep remissions today, and which baseline tests you must complete before taking your first dose of therapy.

📖 Key Terms in Plain English

Before reviewing your lab results, here is a plain-language translation of the six key terms used across all myeloma staging reports:

Term	Plain-English Meaning
Beta-2 Microglobulin (sβ2M)	A small protein shed by myeloma cells and cleared by the kidneys; acts as a dual gauge of total myeloma cell volume and kidney filtering speed.
Serum Albumin	The main nourishing protein in your blood; lower levels (< 3.5 g/dL or < 35 g/L) reflect higher myeloma-driven inflammation (interleukin-6 activity) in the body.
LDH (Lactate Dehydrogenase)	A routine blood enzyme that acts as a cellular "speedometer"—elevated LDH above the lab's upper limit of normal indicates rapid myeloma cell turnover.
iFISH Testing	Short for interphase Fluorescence In Situ Hybridization—a genetic test on bone marrow plasma cells that detects chromosome deletions or swaps, revealing the tumor's "genetic personality."
CD138 Enrichment	A mandatory laboratory step using magnetic beads to isolate pure myeloma cells from bone marrow liquid before running FISH, preventing false "normal" genetic results.
MRD Negativity	Short for Minimal Residual Disease negativity—an ultra-deep remission milestone where flow cytometry or DNA sequencing finds 0 myeloma cells among 100,000 (10⁻⁵) to 1,000,000 (10⁻⁶) normal marrow cells.

1. Why "Stage III" Myeloma Is Nothing Like Terminal Solid Cancer

Blood Cancer vs. Solid Tumors: A Completely Different Rulebook

In solid oncology (such as lung, breast, or colorectal cancer), staging is anatomical. A tumor begins as a localized mass in a single organ (Stage I); if cancer cells break away and colonize distant organs like the liver or brain, it becomes Stage IV (metastatic), where surgical removal is rarely possible.

Multiple myeloma is a hematologic (blood and immune system) cancer. Healthy plasma cells naturally reside throughout the entire bone marrow system—from the spine and pelvis to the ribs and skull. Having myeloma cells in multiple bones at diagnosis is not anatomical metastasis; it simply reflects how blood and marrow cells naturally circulate.

Feature	Solid Tumors (Stage IV Lung or Breast Cancer)	Multiple Myeloma (ISS / R-ISS Stage III)
What Staging Measures	Anatomical spread: Has a primary solid mass invaded distant visceral organs?	Biochemical load & genetics: How much protein is shed, how are the kidneys filtering, and which chromosome changes are present?
Highest Stage Number	Stage IV (Stages I through IV)	Stage III in ISS and R-ISS (or Stage IV in the 4-tier R2-ISS point calculator)
Can Kidneys Inflate the Stage?	❌ No. Kidney function does not alter anatomical tumor staging.	✅ Yes. Sluggish kidneys trap sβ2M in the blood (≥ 5.5 mg/L), placing a patient into ISS Stage III even with moderate tumor mass.
Primary Treatment Modality	Surgery is no longer curative in late stages; systemic therapy is often palliative.	Systemic targeted & immune therapy from Day 1 that reaches every bone marrow niche simultaneously.
Remission & Survival Potential	Distant solid organ metastasis is rarely curable.	✅ Highly responsive: Stage III patients routinely achieve Complete Response (CR), MRD negativity, and long-term survival.

What This Means for You: Never view "Stage III Multiple Myeloma" as a terminal sentence. If excess free light chains temporarily slow down your kidney filtration at diagnosis, your blood sβ2M can easily climb above 5.5 mg/L, automatically assigning you ISS Stage III. Once modern four-drug induction therapy clears the light chains and restores kidney function, your long-term outlook can be remarkably strong.

Data Sources: NCCN Guidelines v2.2027; IMF Patient Handbook; IMS/IMWG Consensus Guidelines.

2. Decoding ISS, R-ISS, and R2-ISS: How Doctors Score Your Stage

Over the past twenty years, international myeloma groups have refined the staging system twice to combine blood markers with bone marrow genetics:

ISS (International Staging System, 2005): Uses 2 routine blood tests (sβ2M and Albumin) to measure overall tumor bulk and kidney clearance.
R-ISS (Revised ISS, 2015): Adds serum LDH plus 3 high-risk FISH chromosome abnormalities to capture how aggressively the cells behave. (Currently the primary standard across international guidelines.)
R2-ISS (Second Revision of ISS, 2022 / NCCN v2.2027): Uses an additive point-scoring calculator (incorporating chromosome 1q21+) to split the overly broad R-ISS Stage II group into four distinct risk tiers.

Part A: Comparing ISS and R-ISS Criteria Side by Side

Stage	ISS Criteria (2 Blood Tests Only)	R-ISS Criteria (ISS + iFISH Genetics + LDH)	Plain-English Meaning
Stage I	• sβ2M < 3.5 mg/L; AND • Albumin ≥ 3.5 g/dL (≥ 35 g/L)	• ISS Stage I; AND • Standard-risk iFISH; AND • Normal serum LDH	✅ Lower Risk: Low tumor load, preserved kidney clearance, slow cell turnover, and calm genetics.
Stage II	• Neither Stage I nor Stage III (sβ2M 3.5–5.4 mg/L, or sβ2M < 3.5 mg/L with Albumin < 3.5 g/dL [< 35 g/L])	• Neither R-ISS Stage I nor R-ISS Stage III	⚠️ Intermediate Risk: A broad "middle basket" encompassing approximately 60% of all newly diagnosed patients.
Stage III	• sβ2M ≥ 5.5 mg/L (regardless of albumin level)	• ISS Stage III (`sβ2M ≥ 5.5 mg/L`); PLUS • High-risk iFISH (`del(17p)`, `t(4;14)`, or `t(14;16)`) OR High serum LDH (> upper limit of normal)	🚨 Higher Risk: High tumor burden combined with either rapid cell division or high-risk chromosome genetics.

What This Means for You: Notice the crucial difference between ISS Stage III and R-ISS Stage III. If your blood sβ2M is 6.2 mg/L (for example, due to mild kidney strain), you are classified as ISS Stage III. However, if your bone marrow iFISH genetics are standard-risk and your blood LDH is normal, you are reclassified down to R-ISS Stage II. Always ask your hematologist for your R-ISS or R2-ISS stage rather than looking at ISS alone.

Part B: The R2-ISS Point Calculator (Unpacking the "Middle 60%")

Because R-ISS Stage II groups together roughly 60% of all patients—mixing individuals who behave like low-risk patients with those who behave like high-risk patients—the European Myeloma Network (EMN) and IMWG developed the R2-ISS additive scoring system (adopted in NCCN Guidelines v2.2027).

Instead of rigid categories, R2-ISS adds up individual risk points from your baseline blood work and bone marrow FISH panel:

Baseline Risk Factor	Points Added	Biological Meaning in Plain English
ISS Stage III (`sβ2M ≥ 5.5 mg/L`)	+1.5 points	High baseline tumor burden or impaired kidney clearance of sβ2M.
ISS Stage II	+1.0 point	Moderate tumor burden (`sβ2M 3.5–5.4 mg/L`) or lower serum albumin (`< 3.5 g/dL` [`< 35 g/L`]).
`del(17p)` on iFISH	+1.0 point	Loss of the short arm of chromosome 17, deleting the critical TP53 "tumor brake" gene.
`t(4;14)` on iFISH	+1.0 point	Exchange of genetic material between chromosomes 4 and 14 that accelerates plasma cell growth.
High Serum LDH (> lab upper limit)	+1.0 point	Elevated blood enzyme signaling rapid myeloma cell division and metabolic turnover.
`1q21` Gain or Amplification (`+1q`)	+0.5 points	Extra copies (3 or ≥ 4 copies) of chromosome 1q—newly integrated into R2-ISS scoring.

Add your points together to determine your R2-ISS Risk Tier:

R2-ISS Stage	Total Point Score	Share of Patients	Clinical Outlook & Practical Meaning
R2-ISS Stage I (Low Risk)	0 points	19%	✅ Highly favorable biology; achieves prolonged remission with standard frontline regimens.
R2-ISS Stage II (Low-Intermediate)	0.5 to 1.0 point	31%	✅ Favorable-intermediate outlook (such as isolated ISS II or isolated `+1q`); median survival approaches a decade or longer.
R2-ISS Stage III (Intermediate-High)	1.5 to 2.5 points	41%	⚠️ True intermediate-high risk; benefits from anti-CD38 quadruplet induction and close MRD monitoring.
R2-ISS Stage IV (High Risk)	3.0 to 5.0 points	9%	🚨 Combined biochemical and genetic risk; requires intensive quadruplet therapy, transplant evaluation, and dual-agent maintenance.

What This Means for You: If your report places you in the broad "R-ISS Stage II" category, adding up your R2-ISS points brings immediate clarity. Scoring 0.5 to 1.0 point (R2-ISS Stage II) carries a substantially calmer clinical trajectory than scoring 2.0 to 2.5 points (R2-ISS Stage III).

Note

R2-ISS Applies Only at Initial Diagnosis

Both R-ISS and R2-ISS are validated strictly for newly diagnosed patients prior to starting therapy. They are not used to restage patients after remission or during relapse.

Data Sources: D'Agostino et al., J Clin Oncol 2022 (EMN/HARMONY R2-ISS); Palumbo et al., J Clin Oncol 2015 (IMWG R-ISS); NCCN Guidelines v2.2027 (MYEL-B).

3. Beyond Stage Numbers: Your Tumor's "Genetic Personality" (mSMART 4.0 & IMS/IMWG Consensus)

The Paradigm Shift: Why a Single Chromosome Change Is Not Always High-Risk

Historically, seeing t(4;14), t(14;16), or +1q on a bone marrow FISH report automatically classified a patient as "high-risk." However, the landmark IMS/IMWG Consensus Genomic Staging (CGS) and Mayo Clinic mSMART 4.0 guidelines have introduced a major refinement:

Important

The "Double-Hit" Principle: Genetic Context Matters

Modern genomic studies prove that an isolated 1q21 gain (3 copies) or an isolated t(4;14) without concurrent chromosome 1 abnormalities often responds nearly as well as standard-risk myeloma when treated with modern four-drug regimens. True high-risk biology is driven by del(17p) in ≥ 20% of clonal plasma cells, a TP53 mutation, or "Double-Hit" combinations where two or more high-risk lesions stack together.

Reading Your Bone Marrow iFISH & NGS Genomic Report

Genetic Finding on CD138-iFISH / NGS	Plain-English Translation	Risk Tier (mSMART 4.0 & IMS/IMWG Consensus)
Trisomies (extra odd chromosomes: 3, 5, 7, 9, 11, 15, 19, 21) or `t(11;14)` / `t(6;14)`	Extra whole chromosomes (hyperdiploidy) or a balanced swap involving chromosome 11 or 6	✅ Standard Risk: The most common, steadier genetic profiles. (Note: `t(11;14)` also predicts high sensitivity to BCL-2 inhibitors such as venetoclax.)
`del(17p)` (in ≥ 20% of cells) and/or TP53 Gene Mutation	Loss of chromosome 17p or mutation of the TP53 tumor-suppressor gene	🚨 High Risk (or Ultra-High-Risk "Double-Hit" when both `del(17p)` and a TP53* mutation affect both copies)*: Demands uninterrupted frontline and maintenance therapy.
`t(4;14)`, `t(14;16)`, or `t(14;20)`	Swaps involving the immunoglobulin heavy-chain (`IGH`) enhancer on chromosome 14q32	⚠️ Co-Occurrence Dependent / High Risk: Under IMS/IMWG and mSMART 4.0, these translocations confer definitive high-risk behavior primarily when paired with `+1q` or `del(1p32)`.
`1q21` Gain/Amp (`+1q`) & `del(1p32)`	Extra copies of chromosome 1's long arm (`1q`) or deletion on its short arm (`1p32`)	🚨 High Risk When Combined: Isolated `+1q` is intermediate, whereas `+1q` plus `del(1p32)`, biallelic `del(1p32)`, or any two high-risk hits ("Double-Hit") defines high-risk disease.

What This Means for You: Your genetic risk profile directly guides how your hematologist builds your treatment plan:

Standard-Risk Myeloma: Treated with a frontline quadruplet (such as Dara-VRd or Isa-VRd) or triplet regimen, stem cell transplant evaluation, and single-agent maintenance (typically lenalidomide).
High-Risk or Double-Hit Myeloma: Treated with maximum frontline intensity—an anti-CD38 quadruplet regimen (Dara-VRd or Isa-KRd), upfront autologous stem cell transplantation (with consideration of tandem transplant in select cases), and dual-agent maintenance therapy (combining a proteasome inhibitor with an immunomodulatory drug) aimed at achieving and sustaining MRD negativity.

Data Sources: Avet-Loiseau et al., J Clin Oncol 2025 (IMS/IMWG High-Risk Consensus); Mayo Clinic mSMART 4.0; NCCN Guidelines v2.2027.

4. Your Complete 4-Pillar Baseline Workup Checklist (Before Dose #1)

Under NCCN Guidelines (Version 2.2027), every newly diagnosed patient requires four pillars of baseline evaluation before starting systemic chemotherapy or high-dose dexamethasone. Once treatment begins, myeloma cells rapidly dissolve in the marrow and bone lesions start healing, making it impossible to recover missing baseline genetics or establish an MRD tracking sequence later.

Workup Pillar	Mandatory Baseline Tests (NCCN v2.2027)	What It Evaluates	Crucial Patient Action Item
1. Blood Counts & Staging Chemistry	• CBC with differential & peripheral blood smear; • Serum Creatinine, eGFR, Electrolytes, Corrected Calcium, Uric Acid; • Serum Albumin, sβ2M, and LDH; • NT-proBNP (or BNP) & Hepatitis B/C/HIV screening	Evaluates CRAB anemia, calcium, and renal function; calculates ISS score; screens for circulating plasma cells (≥ 5% defines plasma cell leukemia) and cardiac AL amyloidosis.	Confirm that sβ2M, Albumin, and LDH are drawn before IV fluids or steroids alter your baseline blood concentrations.
2. Serum & 24-Hour Urine M-Protein Panel	• Quantitative IgG, IgA, IgM; • Blood SPEP (M-spike) & SIFE (isotype); • Serum Free Light Chains (κ, λ, and FLC ratio); • 24-Hour Urine for Total Protein, UPEP, and UIFE	Identifies your exact heavy/light chain subtype and establishes the quantifiable baseline benchmarks required to grade future remission.	Never skip the 24-hour urine collection. Serum free light chains cannot replace a 24-hour urine UPEP/UIFE for measuring Bence-Jones protein or albuminuria.
3. Bone Marrow Biopsy, CD138-iFISH & MRD ID	• Unilateral bone marrow aspirate & core biopsy (IHC/flow cytometry); • CD138-Enriched iFISH Panel: `del(17p)`, `t(4;14)`, `t(11;14)`, `t(14;16)`, `t(14;20)`, `1q21+`, `del(1p32)`; • TP53 NGS mutation panel; • Baseline Clonotype ID	Confirms ≥ 10% clonal plasma cells, establishes R-ISS / R2-ISS and mSMART 4.0 genetic risk, and records your tumor's unique DNA sequence for future NGS MRD testing.	Ask your team before the biopsy: 1) "Will the lab perform CD138 magnetic enrichment prior to FISH?" and 2) "Are we archiving baseline marrow DNA for clonotype MRD tracking?"
4. Advanced Whole-Body Imaging	• Preferred First-Line: Whole-Body FDG-PET/CT or Whole-Body Low-Dose CT (WBLDCT); • Complementary: Whole-Body or Spine/Pelvis MRI without contrast	Detects osteolytic bone holes (≥ 5 mm), soft-tissue extramedullary plasmacytomas, occult marrow focal lesions (SLiM), and spinal cord compression hazards.	Do not rely on plain X-rays (skeletal survey)—standard X-rays miss 25% to 50% of early lytic bone lesions that low-dose CT and PET-CT readily detect.

What This Means for You: Bring this 4-pillar checklist to your first hematology consultation. Ensuring that CD138-sorted FISH, baseline MRD clonotype identification, 24-hour urine electrophoresis, and whole-body PET-CT or low-dose CT are all completed before your first cycle prevents diagnostic blind spots throughout your treatment journey.

Data Sources: NCCN Guidelines v2.2027 (MYEL-1, MYEL-B, MYEL-C); IMWG Consensus Imaging and MRD Guidelines.

Common Pitfalls to Avoid

Pitfall 1: Treating "Stage III" Myeloma Like Terminal Stage IV Solid Cancer

❌ The Pitfall: Assuming that an ISS Stage III or R-ISS Stage III diagnosis means the disease has spread too far for active treatment to work.

✅ The Right Move: Recognize that myeloma staging is a treatment-matching compass, not a survival ceiling. Roughly one-third of high-risk and Stage III patients who achieve sustained MRD negativity (10⁻⁵ to 10⁻⁶) with modern quadruplet induction and stem cell transplantation achieve long-term outcomes comparable to standard-risk patients.

Pitfall 2: Running Bone Marrow FISH Without "CD138 Plasma Cell Enrichment"

❌ The Pitfall: Having a bone marrow aspirate tested at a non-specialized lab that performs FISH directly on unpurified marrow blood—resulting in a false "normal cytogenetics" report.

✅ The Right Move: Because bone marrow liquid is diluted with normal white blood cells, NCCN (v2.2027) and IMWG guidelines mandate CD138 magnetic cell sorting (enrichment) before running FISH so the probes test pure myeloma cells.

Pitfall 3: Expecting Your Stage Number to Drop After Treatment Works

❌ The Pitfall: Wondering why your medical chart still says "R-ISS Stage II" or "Stage III" a year after your M-protein has dropped to zero.

✅ The Right Move: Keep baseline staging separate from treatment response. Your stage at diagnosis stays permanently locked as a historical reference, while your ongoing success is graded by PR (≥ 50% reduction), VGPR (≥ 90% reduction), CR (Complete Response), and MRD Negativity.

Pitfall 4: Skipping the 24-Hour Urine Jug Because You Had a Blood Free Light Chain Test

❌ The Pitfall: Assuming the convenient blood Serum Free Light Chain (sFLC) assay eliminates the need to collect urine for 24 hours at baseline.

✅ The Right Move: Complete both tests. Guidelines emphasize that blood sFLC cannot replace a 24-hour urine total protein, UPEP, and UIFE for quantifying urinary Bence-Jones light chains or detecting heavy albumin leakage from AL amyloidosis.

Pitfall 5: Starting High-Dose Steroids Before Completing Your Biopsy and PET-CT

❌ The Pitfall: Taking high-dose dexamethasone for several days to relieve back pain right before your scheduled baseline bone marrow biopsy and FDG-PET/CT scan.

✅ The Right Move: Unless managing an acute emergency (such as spinal cord compression or severe hypercalcemia), finish your bone marrow aspirate and FDG-PET/CT first. Steroids rapidly kill plasma cells and shut down tumor glucose uptake, which can ruin baseline FISH/MRD testing and cause false-negative PET-CT scans.

Summary: Your Quick Decision Guide

IMWG R-ISS, EMN R2-ISS & NCCN v2.2027

Myeloma Staging Systems & Baseline Workup Guide

1. Core Staging

ISS & R-ISS (I–III)

Stage I: β2M <3.5 · Alb ≥3.5 · Std FISH

Stage II: Neither Stage I nor Stage III

Stage III: β2M ≥5.5 + (HR FISH or High LDH)

Key Rule: Stage III is not terminal metastatic cancer.

2. Additive Score

R2-ISS (0–5.0 Pts)

ISS Stage III / II+1.5 / +1.0 pt

del(17p) · t(4;14) · High LDH+1.0 pt each

1q21+ Gain / Amp+0.5 pt

Key Rule: Isolated 1q+ (+0.5 pt) alone is Low-Intermediate.

3. Action & Tracking

Day 1 vs. Remission

1. Blood & 24h Urine: sβ2M, Alb, LDH, sFLC, UPEP

2. CD138+ Marrow: Sorted FISH + Bank MRD DNA

3. Pre-Steroid Scan: PET/CT or WBLDCT first!

Key Rule: Finish biopsy & PET-CT before taking steroids.

CD138 Sorting Requirement: Never run bone marrow FISH without CD138 plasma cell enrichment; diluted marrow causes false-normal genetics.

Baseline Snapshot vs. Remission: Your baseline stage never drops to Stage I after treatment; remission is measured by CR and MRD negativity.

Core Takeaways for Your First Oncology Visit

Stage III is a call for strong therapy, not a terminal label: High sβ2M often reflects reversible kidney strain from free light chains rather than unstoppable cancer spread.
Ask for R-ISS, R2-ISS, and "Double-Hit" interpretation: Knowing your exact point score (0 to 5.0 points) and whether chromosome changes occur alone or together prevents both undertreatment and unnecessary anxiety.
Protect your Day 1 baseline workup: Verify that your bone marrow biopsy includes CD138 magnetic enrichment for FISH and DNA clonotype archiving for future NGS MRD tracking before starting therapy.
Focus on your forward milestone—MRD Negativity: Once treatment begins, reaching and sustaining MRD negativity is the single most powerful predictor of long-term remission across all baseline stages.

If your staging results fall into a high-risk or borderline category—or if your initial bone marrow biopsy was performed without CD138-enriched FISH testing—consider consulting a dedicated Multiple Myeloma Specialty Center for a second opinion to optimize your frontline induction and maintenance strategy.

Next Steps & Related Decision Guides

If you have high-risk cytogenetics [del(17p), t(4;14), or 1q21+]: Read our High-Risk Myeloma Guide to explore risk-adapted induction, transplant, and dual-maintenance strategies.
If you are choosing your first-line regimen: Consult our Frontline Treatment Comparison Playbook and Standard Clinical Pathway for quadruplet vs. triplet decision matrices.
If you need to understand bone marrow and imaging tests: Review our Bone Marrow Biopsy Guide and Whole-Body Imaging Guide.
If you want to understand long-term survival and functional cure: Read our Functional Cure & Curability Guide.
If you are exploring frontline clinical studies: Search open trials in the CMDN Clinical Trials Navigator.

References

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma, Version 2.2027.
D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology. 2022;40(29):3406-3418.
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology. 2015;33(26):2863-2869.
Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society / International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. Journal of Clinical Oncology. 2025;43:2739-2751.
Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. mSMART 4.0: Classification and Risk-Adapted Management of Newly Diagnosed Multiple Myeloma.
Hillengass J, Usmani S, Rajkumar SV, et al. International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet Oncology. 2019;20(6):e302-e312.
International Myeloma Foundation (IMF) & Multiple Myeloma Research Foundation (MMRF). Patient Handbook & Diagnostic Staging Guidelines.

This clinical decision guide is synthesized from international consensus guidelines and peer-reviewed literature for educational purposes only. It does not substitute for professional medical care. Consult your treating hematology-oncology team regarding diagnostic and treatment decisions.

Your myeloma care companion

CMDN Care · Myeloma Companion

Organize your lab reports, follow biomarker trends, and prepare questions for your care team with CMDN’s English-language companion for myeloma patients and caregivers.

Open CMDN Care How CMDN Care works

Lab report OCR

Review results extracted from your reports.

Biomarker trends

Keep follow-up results in one place.

Visit preparation

Bring your questions to your care team.

Your share could light up hope for another patient 💛

FAQs

Does Stage III multiple myeloma mean my cancer is terminal or untreatable?: No. Unlike solid tumors where Stage IV means distant organ metastasis, multiple myeloma staging only goes up to Stage III (or Stage IV in the R2-ISS point calculator) and measures baseline tumor load, kidney filtering of sβ2M, and cell division speed. With modern anti-CD38 quadruplet regimens and stem cell transplantation, many Stage III patients achieve Complete Response (CR), Minimal Residual Disease (MRD) negativity, and multi-year survival.
What is the difference between ISS, R-ISS, and R2-ISS staging?: ISS (2005) uses only two blood tests—serum beta-2 microglobulin (sβ2M) and albumin—to estimate tumor bulk. R-ISS (2015) is the current universal standard that adds serum LDH and three high-risk FISH chromosome abnormalities: del(17p), t(4;14), and t(14;16). R2-ISS (2022, endorsed in NCCN v2.2027) uses an additive 0 to 5.0 point score (adding chromosome 1q21 gain/amplification) to divide the broad R-ISS Stage II group into four sharper risk tiers.
Why did my elevated kidney creatinine automatically put me into ISS Stage III?: Beta-2 microglobulin (sβ2M) is a small protein shed by myeloma cells that is normally filtered out by the kidneys. When myeloma free light chains temporarily slow down kidney function, sβ2M builds up in the bloodstream to ≥ 5.5 mg/L, automatically triggering ISS Stage III even if your genetic risk is standard. If your bone marrow FISH genetics and blood LDH are normal, your R-ISS stage steps down to Stage II.
If my FISH report shows a 1q21 gain (+1q) or t(4;14), am I automatically high-risk?: Not necessarily. Under the latest IMS/IMWG Consensus Genomic Staging and Mayo Clinic mSMART 4.0 criteria, an isolated 1q21 gain adds only +0.5 points in R2-ISS (low-intermediate risk), and an isolated t(4;14) without chromosome 1 abnormalities often responds nearly as well as standard-risk disease. True high-risk biology is defined by del(17p) in ≥ 20% of plasma cells, a TP53 mutation, or 'Double-Hit' combinations where t(4;14)/t(14;16) co-occurs with +1q or del(1p32).
Will my myeloma stage drop back to Stage I once my M-protein reaches zero?: No. Your ISS, R-ISS, or R2-ISS stage is a one-time baseline snapshot recorded at initial diagnosis and remains fixed forever. Once treatment begins, your hematologist measures success using IMWG response criteria—Partial Response (PR, ≥ 50% drop), Very Good Partial Response (VGPR, ≥ 90% drop), Complete Response (CR), and MRD negativity (fewer than 1 myeloma cell per 100,000 to 1,000,000 bone marrow cells).
What is the most important mistake to avoid during my baseline bone marrow biopsy?: Never allow a lab to run bone marrow FISH genetic testing without CD138 magnetic plasma cell enrichment, and never start high-dose steroids before your biopsy and FDG-PET/CT scan are finished (unless facing a medical emergency). Without CD138 purification, diluted marrow samples yield false-normal genetic results, and early steroid pulses can obscure baseline PET-CT bone lesions and MRD clonotype identification.

References used for this guide

Sincere thanks to the following authoritative institutions
for their academic support:

Lighting the hope of survival
for myeloma patients globally

Medical Disclaimer: Information provided on this site is synthesized from authoritative consensus guidelines for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult your qualified healthcare team regarding clinical decisions.

This article is reviewed and published by the CMDN Editorial Team

Last updated: 2026-10-26

Get Support